Strides Arcolab is trading lower by 6% to Rs 928 after reporting a 10.3% year-on-year (yoy) drop in net profit at Rs 61 crore for the fourth quarter ended December 31, 2012 (Q4) due to lower operational income and forex gain. Analyst on an average had expected profit of Rs 76 crore.
Total income from operations in Q3 declined 8% to Rs 633 crore on yoy basis. The company reported a forex gain of Rs 10.19 crore as against Rs 50.57 crore in the same quarter previous year.
“Licensing income impacted by Rs 48 crore as the company bought back key product portfolios,” Strides Arcolab said in a statement.
Meanwhile, the pharmaceutical company said that it has entered into a definitive agreement for the sale of its specialties subsidiary, Agila Specialties Private Limited, to US-based Mylan Inc for a cash consideration of approximately Rs 8,610 crore and potential additional consideration of approximately Rs 1,345 crore.
Strides Arcolab expects almost 100% growth in EBITDA (earnings before interest, taxes, depreciation, and amortization), excluding specialties business, to Rs 200 crore in 2013 against Rs 103 crore in 2012 and a significant margin expansion on revenues of about Rs 1,000 crore.
The stock opened at Rs 1,115 and hit a low of Rs 881 on NSE. The counter has seen huge trading activity with a combined 3.47 million shares already changed hands till 1038 hours against an average sub one million shares that were traded daily in past two weeks.
Total income from operations in Q3 declined 8% to Rs 633 crore on yoy basis. The company reported a forex gain of Rs 10.19 crore as against Rs 50.57 crore in the same quarter previous year.
“Licensing income impacted by Rs 48 crore as the company bought back key product portfolios,” Strides Arcolab said in a statement.
Meanwhile, the pharmaceutical company said that it has entered into a definitive agreement for the sale of its specialties subsidiary, Agila Specialties Private Limited, to US-based Mylan Inc for a cash consideration of approximately Rs 8,610 crore and potential additional consideration of approximately Rs 1,345 crore.
Strides Arcolab expects almost 100% growth in EBITDA (earnings before interest, taxes, depreciation, and amortization), excluding specialties business, to Rs 200 crore in 2013 against Rs 103 crore in 2012 and a significant margin expansion on revenues of about Rs 1,000 crore.
The stock opened at Rs 1,115 and hit a low of Rs 881 on NSE. The counter has seen huge trading activity with a combined 3.47 million shares already changed hands till 1038 hours against an average sub one million shares that were traded daily in past two weeks.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%